Log In
Print
BCIQ
Print
Print this Print this
 

Xclair

  Manage Alerts
Collapse Summary General Information
Company Hexim Pharmaceuticals Inc.
DescriptionCream in a hydrolipidic base
Molecular Target Not applicable
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsManage and relieve symptoms of radiation-induced dermatitis
Regulatory Designation

Partner

Menarini Group; Quintiles Transnational Holdings Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1.8M

$1.8M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today